Telehealth & Digital Health

At Abarca Forward 2026, industry stakeholders and federal officials built a new playbook to transform the universally broken prior authorization process.

P4ML joins the Orphan Therapeutics Accelerator to bring shelved cures to patients, leveraging a new non-profit model and expanding access to the MENA region.

As Aura presents its precision oncology pipeline at key conferences, investors will weigh the promise of its lead drug against a challenging financial landscape.

Plus Therapeutics' REYOBIQ gains a crucial CPT code, a vital step in bringing this targeted radiotherapy to patients with aggressive brain cancers.

A novel nasal spray for progressive MS shows it can calm brain inflammation and boost neuroprotection, offering new hope for a difficult-to-treat disease.

With its stock lagging, TScan Therapeutics will use a key conference to highlight upcoming clinical trial data and convince investors of its pipeline's value.

A landmark partnership aims to bring precision cancer therapy, or Theranostics, to millions in underserved nations, backed by a major WHO resolution.

The biotech firm secures major funding to push its promising head and neck cancer drug, ficerafusp alfa, toward regulatory approval and commercial launch.

A landmark study confirms a minimally invasive radiofrequency device is highly effective for chronic rhinitis, offering lasting relief beyond traditional sprays.

With new backing from One Six 8 Ventures, health tech firm Respiree accelerates its US and Canadian expansion of its FDA-cleared AI platform.

Dupixent's landmark FDA approval offers a new, surgery-sparing option for a debilitating sinus disease, but questions of access and cost remain.

A new report shows most medical practices are flying blind, with only 7% confident in tracking revenue, leading to massive, preventable financial losses.

Despite missing its primary goal, Cadrenal Therapeutics' drug CAD-1005 drastically cut deadly blood clots, setting up a crucial FDA meeting for a new path forward.

New Phase 1b data for oral drug pociredir reveals a robust boost in fetal hemoglobin, as Fulcrum Therapeutics secures a financial runway into 2029.

After an 8-year hiatus, Elizabeth Arden launches Eternal Aura. A look at the strategy combining a new star, wellness science, and heritage to reclaim its spot.

With promising data in cancer and eczema, all eyes are on Corvus Pharmaceuticals as it presents its lead drug at a major healthcare conference this week.

After gaining FDA alignment, INmune Bio is advancing its inflammation-targeting drug, XPro1595, offering a novel and potentially safer approach for patients.

The Biocodex Microbiota Foundation opens its 10th annual grant, committing a total of half a million dollars to shape the future of U.S. gut health science.

A landmark FDA approval for Bracco's VUEWAY allows high-quality MRI scans in neonates with half the standard gadolinium dose, easing safety concerns.

A Swiss firm begins human trials for a non-glucose dialysis solution, aiming to end a 30-year reliance on problematic treatments for kidney patients.